ChemoCentryx, Inc. (CCXI) Analysts See $-0.19 EPS as of May, 9

April 17, 2018 - By Joseph Norton

ChemoCentryx, Inc. (NASDAQ:CCXI) Corporate Logo
During 2017 Q4 the big money sentiment increased to 1.3. That’s change of 0.16, from 2017Q3’s 1.14. 6 investors sold all, 21 reduced holdings as ChemoCentryx, Inc. ratio is positive. 28 increased holdings while 7 funds acquired holdings. Funds hold 23.51 million shares thus 1.03% less from 2017Q3’s 23.75 million shares.
Federated Pa has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Fernwood Investment Mngmt Ltd Limited Liability Company stated it has 10,000 shs or 0.03% of all its holdings. Legal And General Group Inc Public Limited Co holds 5,113 shs. Bnp Paribas Arbitrage Sa holds 5,178 shs. 121,132 were reported by Tiaa Cref Investment Mgmt Limited Liability Company. Paw Cap holds 1.2% or 160,000 shs. Schwab Charles Inv Mgmt Inc invested in 0% or 35,200 shs. Renaissance Techs Ltd Liability reported 863,581 shs stake. 443,300 are owned by State Street Corp. Alliancebernstein Ltd Partnership accumulated 37,500 shs. Ameritas Investment Prns reported 0% of its capital in ChemoCentryx, Inc. (NASDAQ:CCXI). Invesco holds 77,660 shs or 0% of its capital. Art Advsr Limited Liability Company holds 11,297 shs or 0% of its capital. State Of Wisconsin Investment Board stated it has 19,000 shs. Los Angeles Cap Mngmt Equity Rech stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI).

Earnings report for ChemoCentryx, Inc. (NASDAQ:CCXI) is awaited On May, 9., according to Faxor. Analysts forecast 58.33 % diference or $-0.19 from the $-0.12 EPS from 2017. Last quarter $0.80 EPS was reported. Analysts sees -123.75 % negative EPS growth this quarter. Its shares touched $10.98 on during the last trading session after 6.15% change.Currently ChemoCentryx, Inc. is uptrending after 81.17% change in last April 17, 2017. CCXI has also 216,807 shares volume. CCXI outperformed by 69.62% the S&P 500.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.The firm is worth $538.80 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).30.5 is the P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn's diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.